Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17157357 | 0.82 | AKR1B1 (0.31) | AKR1B1 | |
| SCHEMBL30769064 | 0.82 | AKR1B1 (0.31) | AKR1B1 | |
| SCHEMBL31535526 | 0.78 | CYP11B1 (0.32) | — | |
| SCHEMBL29386751 | 0.75 | KDM1A (0.34) | KDM1AKDM1BAKR1B1 | |
| SCHEMBL919665 | 0.73 | KDM1A (0.42) | KDM1AKDM1BAKR1B1APEX1 | |
| SCHEMBL1931981 | 0.73 | KDM1A (0.42) | KDM1AKDM1BAKR1B1APEX1 | |
| SCHEMBL2938544 | 0.73 | CES2 (0.41) | TTR | |
| SCHEMBL18101290 | 0.73 | TTR (0.33) | TTR | |
| Phosphine SCHEMBL28191590 | 0.71 | CES2 (0.39) | TTR | |
| SCHEMBL6553272 | 0.71 | KDM1A (0.41) | KDM1AKDM1BAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12134627-B2 | Boron hydroxyl-containing organic compound, method for preparing same and use thereof | JIANGSU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-11-05 | — | — | US | claimed |
| CN-116836194-A | Diboron condensed ring organic compound and preparation method and application thereof | 江苏科技大学 | 2023-10-03 | — | — | CN | claimed |
| US-20230099951-A1 | BORON HYDROXYL-CONTAINING ORGANIC COMPOUND, METHOD FOR PREPARING SAME AND USE THEREOF | JIANGSU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-03-30 | — | — | US | claimed |
| WO-2022104965-A1 | BORON-CONTAINING HYDROXYL ORGANIC COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏科技大学 | 2022-05-27 | — | — | WO | claimed |
| CN-112266393-B | Boron hydroxyl-containing organic compound and preparation method and application thereof | 江苏科技大学 | 2021-07-09 | — | — | CN | claimed |
| CN-112266393-A | Boron hydroxyl-containing organic compound and preparation method and application thereof | 江苏科技大学 | 2021-01-26 | — | — | CN | claimed |
| US-12606740-B2 | Formulations and applications thereof in optoelectronic field | ZHEJIANG BRILLIANT OPTOELECTRONIC TECHNOLOGY CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12584067-B2 | Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic equipment | IDEMITSU KOSAN CO. , LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626555-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| CN-102153441-A | Fluorinated terphenyl liquid crystal compound containing two 3-butenyls and preparation method thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO LTD | 2011-08-17 | — | — | CN | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | BCL2A1, BCL2L1, BCL2L11 | KDM1A 2787/4885KDM1B 2167/4885AKR1B1 1562/4885 |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | KDM1A 4126/4885KDM1B 4308/4885AKR1B1 252/4885 |
| US-20230099951-A1 | BORON HYDROXYL-CONTAINING ORGANIC COMPOUND, METHOD FOR PREPARING SAME AND USE THEREOF | OGFOD1, OCIAD1, OCIAD2 | KDM1A 857/4885KDM1B 622/4885AKR1B1 355/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | KDM1A 3743/4885KDM1B 3605/4885AKR1B1 1788/4885 |
| US-12584067-B2 | Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic equipment | SOD1, RPS4X, RER1 | KDM1A 3007/4885KDM1B 2687/4885AKR1B1 4358/4885 |
| US-12134627-B2 | Boron hydroxyl-containing organic compound, method for preparing same and use thereof | OGFOD1, OCIAD1, OCIAD2 | KDM1A 857/4885KDM1B 622/4885AKR1B1 355/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | KDM1A 4193/4885KDM1B 4613/4885AKR1B1 2487/4885 |
| US-12606740-B2 | Formulations and applications thereof in optoelectronic field | OR10J3, CCR9, CBR1 | KDM1A 3781/4885KDM1B 3517/4885AKR1B1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.